Почетна › Рак на бели дробови со не-мали клетки › Калифорнија › Sacramento
Клинички испитувања за Рак на бели дробови со не-мали клетки во Sacramento, CA
29 студии за Рак на бели дробови со не-мали клетки бараат учесници на локации во и околу Sacramento (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Се регрутираФаза 3
- Kaiser Permanente Downtown Commons, Sacramento
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- и уште 1
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Се регрутираФаза 3
- UC Davis Comprehensive Cancer Center ( Site 3204), Sacramento
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Се регрутираФаза 3
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Се регрутираФаза 3
- Buhler Specialty Pavilion, Sacramento
- Sutter Medical Center, Sacramento Infusion Center, Sacramento
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Се регрутираФаза 2
- UC Davis Comprehensive Cancer Center, Sacramento
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Се регрутираФаза 3
- University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Се регрутираФаза 1/2
- UC Davis Comprehensive Cancer Center, Sacramento
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Се регрутираФаза 2
- UC Davis Cancer Center (Data Collection Only), Sacramento
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Се регрутираФаза 2
- UC Davis Comprehensive Cancer Center, Sacramento
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Се регрутираФаза 1/2
- University of California Davis Comprehensive Cancer Center, Sacramento
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Се регрутираФаза 3
- University of California Davis Comprehensive Cancer Center, Sacramento
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
Се регрутираФаза 2
- University of California Davis Comprehensive Cancer Center, Sacramento
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Се регрутираФаза 1/2
- University of California, Davis Comprehensive Cancer Center, Sacramento
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Се регрутираФаза 1
- University of California Davis Comprehensive Cancer Center, Sacramento
- University of California, Davis Medical Center, Sacramento
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
Се регрутира
- University of California, Davis, Sacramento
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Се регрутираФаза 1/2
- UC Davis, Davis Comprehensive Cancer Center, Sacramento
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Се регрутираФаза 3
- Sutter Institute for Medical Research, Sacramento
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Се регрутираФаза 2
- Kaiser Permanente Downtown Commons, Sacramento
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Се регрутираФаза 1
- University of California, Davis Comprehensive Cancer Center, Sacramento
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Се регрутираФаза 1
- University of California Davis, Sacramento
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2/3
- Kaiser Permanente Downtown Commons, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2
- Sutter Medical Center Sacramento, Sacramento
- University of California Davis Comprehensive Cancer Center, Sacramento
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Се регрутираФаза 1/2
- University of California, Davis Comprehensive Cancer Center, Sacramento
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Се регрутираНабљудувачка студија
- Kaiser Permanente Downtown Commons, Sacramento
- Mercy Cancer Center - Sacramento, Sacramento
- Kaiser Permanente-South Sacramento, Sacramento
- и уште 1
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
Се регрутираФаза 1
- The University of California Davis Comprehensive Cancer Center, Sacramento
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
Се регрутираФаза 1
- The University of California Davis Comprehensive Cancer Center, Sacramento
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Се регрутираФаза 1/2
- VA Northern California Health Care System, Mather, CA, Sacramento
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Се регрутираФаза 1
- University of California-Davis, Sacramento
Испитувања за Рак на бели дробови со не-мали клетки во други градови
- Houston, TX145 студии
- New York City, NY121 студија
- Arlington, VA104 студии
- Nashville, TN97 студии
- Boston, MA90 студии
- Los Angeles, CA87 студии
- St. Louis, MO73 студии
- Chicago, IL61 студија
- Baltimore, MD60 студии
- San Antonio, TX59 студии
- Columbus, OH57 студии
- Washington, DC55 студии
Други студии во Sacramento
- Рак на бели дробови22 студии
- Рак на дојка20 студии
- Рак на простата19 студии
- Метастатски карцином16 студии
- Акутна миелоидна леукемија12 студии
- Срцева слабост12 студии
- Карцином на панкреасот12 студии
- Рак (сите типови)11 студии
- Рак на дебелото црево11 студии
- Рак на бешиката10 студии
- Колоректален карцином10 студии
- Дијабетес тип 29 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.